{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:36:44Z","timestamp":1789774604271,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Differentiation syndrome (DS) is a serious complication with an unclear pathogenesis that arises following all-trans retinoic acid (ATRA) or arsenic trioxide induction therapy in acute promyelocytic leukemia (APL). DS symptoms include pyrexia, respiratory compromise, increased body mass, fluid accumulation, pulmonary infiltrates, hypotension, tachycardia, edema, and sepsis. It can also affect the kidneys and the central nervous system. The standard treatment to counteract DS involves the temporary cessation of ATRA or arsenic trioxide treatment and the administration of high-dose steroids to mitigate the inflammatory response. If left untreated, DS can be fatal. Further research has revealed that the inability to promptly recognize intracranial hemorrhage (ICH) in patients with APL may result in lethal consequences, with the cytokine storm identified as the principal factor in this scenario as well. ATRA therapy is known to induce transglutaminase 2 (TG2), which functions as a catalyst for DS development. In this study, we used NB4 cell lines and cells from a human patient with APL to investigate the ex vivo effects of ATRA and 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    cotreatment on NF-\u03baB-regulated luciferase reporter gene activity. ATRA alone substantially enhanced cellular NF-\u03baB luciferase reporter gene activity, whereas 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    dose-dependently reduced this activity. During ATRA-initiated cell maturation, 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    , known as calcidiol, suppressed the mRNA expression of NF-\u03baB (\n                    <jats:italic>p65\/p50<\/jats:italic>\n                    ) and Rel family members, as well as the expression of genes associated with increased NF-\u03baB activity. 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    also inhibited the ATRA-induced production of cytokines (e.g., IL-8), including IL-1\u03b2, TNF-\u03b1, and MCP-1, associated with the \u201ccytokine storm.\u201d Combined treatment with ATRA plus 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    reduced cellular phospho-p65 and transglutaminase 2 (TG2) levels and increased the level of inhibitor of Rel (I\u03baB), thereby attenuating the cytokine storm. These findings provide a molecular interpretation for clinical DS and IHC observations and may support future exploration of ATRA plus 25(OH)D\n                    <jats:sub>3<\/jats:sub>\n                    cotreatment as a therapy for APL.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08109-7","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:08:09Z","timestamp":1762178889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-inflammatory 25(OH)D3, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"K\u00e1roly","family":"Jambrovics","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedean","family":"Al-Hadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"M\u00e1zl\u00f3-T\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Szatmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"Dob\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m","family":"J\u00f3na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-6838","authenticated-orcid":false,"given":"G\u00e1bor","family":"Koncz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6654-7234","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Balajthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"8109_CR1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood.V57.6.1000.1000","volume":"57","author":"T Breitman","year":"1981","unstructured":"Breitman T, Collins SJ, Keene B. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57:1000\u20134.","journal-title":"Blood"},{"key":"8109_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1182\/blood.V77.5.1080.1080","volume":"77","author":"M Lanotte","year":"1991","unstructured":"Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t (15; 17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080\u20136.","journal-title":"Blood"},{"key":"8109_CR3","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/blood-2004-02-007948","volume":"108","author":"Z Balajthy","year":"2006","unstructured":"Balajthy Z, Csom\u00f3s K, V\u00e1mosi G, Sz\u00e1nt\u00f3 A, Lanotte M, F\u00e9s\u00fcs L. Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood. 2006;108:2045\u201354.","journal-title":"Blood"},{"key":"8109_CR4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2010-01-266064","volume":"116","author":"K Csom\u00f3s","year":"2010","unstructured":"Csom\u00f3s K, N\u00e9met I, F\u00e9s\u00fcs L, Balajthy Z. Tissue transglutaminase contributes to the all-trans-retinoic acid\u2013induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood. 2010;116:3933\u201343.","journal-title":"Blood"},{"key":"8109_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, Ray\u00f3n C, Parody R, de la Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775\u201383.","journal-title":"Blood"},{"key":"8109_CR6","first-page":"541","volume":"67","author":"D Datta","year":"2003","unstructured":"Datta D, Gerardi DA. Retinoic acid syndrome. Conn Med. 2003;67:541\u20133.","journal-title":"Conn Med"},{"key":"8109_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11684-021-0890-1","volume":"16","author":"F Dong","year":"2022","unstructured":"Dong F, Chen L, Zhao C, Li X, Tan Y, Song H, et al. Predictive values of plasma TNF\u03b1 and IL-8 for intracranial hemorrhage in patients with acute promyelocytic leukemia. Front Med. 2022;16:909\u201318.","journal-title":"Front Med"},{"key":"8109_CR8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3109\/13880209.2014.988274","volume":"53","author":"M Giammanco","year":"2015","unstructured":"Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, et al. Vitamin D in cancer chemoprevention. Pharm Biol. 2015;53:1399\u2013434.","journal-title":"Pharm Biol"},{"key":"8109_CR9","doi-asserted-by":"publisher","first-page":"19450","DOI":"10.1074\/jbc.M113.467670","volume":"288","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor \u03baB activation by interacting with I\u03baB kinase \u03b2 protein. J Biol Chem. 2013;288:19450\u20138.","journal-title":"J Biol Chem"},{"key":"8109_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00403-004-0509-9","volume":"296","author":"JL Riis","year":"2004","unstructured":"Riis JL, Johansen C, Gesser B, M\u00f8ller K, Larsen CG, Kragballe K, et al. 1\u03b1, 25 (OH) 2 D 3 regulates NF-\u03baB DNA binding activity in cultured normal human keratinocytes through an increase in I\u03baB\u03b1 expression. Arch Dermatol Res. 2004;296:195\u2013202.","journal-title":"Arch Dermatol Res"},{"key":"8109_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1017\/S0007114516000696","volume":"115","author":"R Dou","year":"2016","unstructured":"Dou R, Ng K, Giovannucci EL, Manson JE, Qian ZR, Ogino S. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr. 2016;115:1643\u201360.","journal-title":"Br J Nutr"},{"key":"8109_CR12","doi-asserted-by":"crossref","unstructured":"Lopez-Caleya JF, Ortega-Val\u00edn L, Fern\u00e1ndez-Villa T, Delgado-Rodr\u00edguez M, Mart\u00edn-S\u00e1nchez V, Molina AJ. The role of calcium and vitamin D dietary intake on risk of colorectal cancer: Systematic review and meta-analysis of case\u2013control studies. Cancer Causes Control. 2022;33:167\u201382.","DOI":"10.1007\/s10552-021-01512-3"},{"key":"8109_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clnesp.2018.12.085","volume":"30","author":"S Hossain","year":"2019","unstructured":"Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB, Wood RJ. Vitamin D and breast cancer: a systematic review and meta-analysis of observational studies. Clin Nutr ESPEN. 2019;30:170\u201384.","journal-title":"Clin Nutr ESPEN"},{"key":"8109_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0968-0004(02)02182-5","volume":"27","author":"L Fesus","year":"2002","unstructured":"Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27:534\u20139.","journal-title":"Trends Biochem Sci"},{"key":"8109_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1152\/physrev.00019.2013","volume":"94","author":"RL Eckert","year":"2014","unstructured":"Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014;94:383\u2013417.","journal-title":"Physiol Rev"},{"key":"8109_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mc.22986","volume":"58","author":"RL Eckert","year":"2019","unstructured":"Eckert RL. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target. Mol Carcinogenesis. 2019;58:837\u201353.","journal-title":"Mol Carcinogenesis"},{"key":"8109_CR17","doi-asserted-by":"publisher","first-page":"e0149388","DOI":"10.1371\/journal.pone.0149388","volume":"11","author":"J Cao","year":"2016","unstructured":"Cao J, Huang W. Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment. PloS One. 2016;11:e0149388.","journal-title":"PloS One"},{"key":"8109_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41419-023-05748-6","volume":"14","author":"K Jambrovics","year":"2023","unstructured":"Jambrovics K, Bot\u00f3 P, Pap A, Sarang Z, Kolosty\u00e1k Z, Czimmerer Z, et al. Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death. Cell Death Dis. 2023;14:217.","journal-title":"Cell Death Dis"},{"key":"8109_CR19","unstructured":"Jambrovics K, Keresztessy Z, Moln\u00e1r O, F\u00e9s\u00fcs L, Balajthy Z, editors. Evaluation of the pathobiological function of tissue transglutaminase 2 (TG2) in NB4, acute promyelocytic leukaemia cell lines. Transglutaminases Med. 2017;10:1842."},{"key":"8109_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28:20\u201338.","journal-title":"Apoptosis"},{"key":"8109_CR21","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/cancers14071671","volume":"14","author":"P Cetraro","year":"2022","unstructured":"Cetraro P, Plaza-Diaz J, MacKenzie A, Abad\u00eda-Molina F. A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer. CANCERS. 2022;14:1671.","journal-title":"CANCERS"},{"key":"8109_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745\u201356.","journal-title":"Nat Rev Immunol"},{"key":"8109_CR23","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1128\/MCB.19.5.3485","volume":"19","author":"GA Webster","year":"1999","unstructured":"Webster GA, Perkins ND. Transcriptional cross talk between NF-\u03baB and p53. Mol Cell Biol. 1999;19:3485\u201395.","journal-title":"Mol Cell Biol"},{"key":"8109_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1359-6101(00)00018-6","volume":"12","author":"D Joyce","year":"2001","unstructured":"Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-\u03baB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73\u201390.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8109_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1042\/BST20130156","volume":"42","author":"AC Ledoux","year":"2014","unstructured":"Ledoux AC, Perkins ND. NF-\u03baB and the cell cycle. Biochem Soc Trans. 2014;42:76\u201381.","journal-title":"Biochem Soc Trans"},{"key":"8109_CR26","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1182\/blood.V83.11.3264.3264","volume":"83","author":"C Dubois","year":"1994","unstructured":"Dubois C, Schlageter MH, de Gentile A, Guidez F, Balitrand N, Toubert ME, et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood. 1994;83:3264\u201370.","journal-title":"Blood"},{"key":"8109_CR27","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","volume":"114","author":"M Luesink","year":"2009","unstructured":"Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114:5512\u201321.","journal-title":"Blood"},{"key":"8109_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.clnu.2023.05.009","volume":"42","author":"T Gwenzi","year":"2023","unstructured":"Gwenzi T, Zhu A, Schrotz-King P, Sch\u00f6ttker B, Hoffmeister M, Brenner H. Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials. Clin Nutr. 2023;42:1142\u201350.","journal-title":"Clin Nutr"},{"key":"8109_CR29","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1007\/s00018-003-3110-z","volume":"60","author":"C Akgul","year":"2003","unstructured":"Akgul C, Edwards S. Regulation of neutrophil apoptosis via death receptors. Cell Mol Life Sci. 2003;60:2402\u20138.","journal-title":"Cell Mol Life Sci"},{"key":"8109_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/00024382-200309000-00005","volume":"20","author":"D Tamandl","year":"2003","unstructured":"Tamandl D, Bahrami M, Wessner B, Weigel G, Ploder M, F\u00fcrst W, et al. Modulation of toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin-6 enhances lipopolysaccharide activity. Shock. 2003;20:224\u20139.","journal-title":"Shock"},{"key":"8109_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","volume":"23","author":"G Van Loo","year":"2023","unstructured":"Van Loo G, Bertrand MJ. Death by TNF: a road to inflammation. Nat Rev Immunol. 2023;23:289\u2013303.","journal-title":"Nat Rev Immunol"},{"key":"8109_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cancers12030648","volume":"12","author":"K Jambrovics","year":"2020","unstructured":"Jambrovics K, Uray I, Keillor JW, F\u00e9s\u00fcs L, Balajthy Z. Benefits of combined all-trans retinoic acid and arsenic trioxide treatment of acute promyelocytic leukemia cells and further enhancement by inhibition of atypically expressed transglutaminase 2. Cancers. 2020;12:648.","journal-title":"Cancers"},{"key":"8109_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3324\/haematol.2018.192823","volume":"104","author":"K Jambrovics","year":"2018","unstructured":"Jambrovics K, Uray I, Keresztessy Z, Keillor JW, F\u00e9s\u00fcs L, Balajthy Z. Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kB activation. Haematologica. 2018;104:505.","journal-title":"Haematologica"},{"key":"8109_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.leukres.2005.01.005","volume":"29","author":"M Shibakura","year":"2005","unstructured":"Shibakura M, Niiya K, Niiya M, Asaumi N, Yoshida C, Nakata Y, et al. Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells. Leuk Res. 2005;29:755\u20139.","journal-title":"Leuk Res"},{"key":"8109_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000510040","volume":"49","author":"S Wintzer","year":"2020","unstructured":"Wintzer S, Heckmann JG, Huttner HB, Schwab S. Dexamethasone in patients with spontaneous intracerebral hemorrhage: an updated meta-analysis. Cerebrovasc Dis. 2020;49:495\u2013502.","journal-title":"Cerebrovasc Dis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08109-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:08:11Z","timestamp":1762178891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08109-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8109"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08109-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"787"}}